Identifying a combination of biomarkers to predict treatment response to nabilone for the treatment of agitation in Alzheimer's disease – a secondary analysis
Participants with higher levels of inflammation, oxidative stress, and cholesterol metabolite were more likely to benefit from nabilone for agitation in AD. A combination of biomarkers could help in distinguishing responders and non-responders to nabilone.
Authors
- Ana C. Andreazza (ORCID: https://orcid.org/0000-0002-4323-7273)
- Alex Kiss
- Hui Jue Wang
- Krista L. Lanctôt (ORCID: https://orcid.org/0000-0001-7024-6637)
- Oriel J. Feldman (ORCID: https://orcid.org/0000-0002-5201-133X)
- Nicolaas Paul L.G. Verhoeff
- Myuri Ruthirakuhan
- Nathan Herrmann
- Damien Gallagher
- Sandra E. Black
Institutions
- Sunnybrook Health Science Centre (CA)
- Centre for Addiction and Mental Health (CA)
- University of Toronto (CA)
- Health Sciences Centre (CA)
- Baycrest Hospital (CA)
- Sunnybrook Hospital (CA)
- Sunnybrook Research Institute
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70857_103580
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00